Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Q4 2013 Earnings Conference Call
March 04, 2014 4:30 PM ET
Elizabeth Davis – Corporate Relations
A. J. Kazimi – Chief Executive Officer
Martin E. Cearnal – Chief Commercial Officer and Senior Vice President
Rick S. Greene – Chief Financial Officer and Vice President-Finance and Accounting
Good afternoon, ladies and gentlemen. And welcome to Cumberland Pharmaceutical’s Fourth Quarter 2013 Earnings Conference Call. During the Company’s presentation all parties will be in a listen-only mode. Following the presentation, conference will be opened for questions. This call is being recorded and a replay will be available for one week, shortly following its conclusion.
At this time, I’d like to turn the call over to Elizabeth Davis who handles, Corporate Relations for Cumberland Pharmaceuticals. Please go ahead.
Hello, everyone. Today we issued a press release featuring our fourth quarter 2013 financial results and company updates. If you have not seen our press release issued today, you can access it on our website at www.cumberlandpharma com. Before we begin, we would like to advise you that this call will include forward-looking statements, which reflect our current views about future events. Such forward-looking statements are subject to risks outlined in the Safe Harbor section of today's press release and are detailed in our 10-K and 10-Q reports on file with SEC. Despite our best efforts, actual results could differ materially from our expectations.
Information shared on the call today should be considered current as of today only, and please remember that the Company assumes no duty to update it. We post and maintain the current version of our corporate presentation as well as other press releases and company updates on the Investors portion of our website. Also, please note that this conference call is being webcast through our website and will be available there.
I’ll now turn the call over to our Chief Executive Officer, A. J. Kazimi.
A. J. Kazimi
Thanks Elizabeth, good afternoon everyone, and thank you for joining us, as we review our 2013 results and discuss our strategy for 2014. With me on today’s call are Cumberland’s Commercial Officer, Marty Cearnal and our Chief Financial Officer, Rick Greene. We’ll start by reviewing 2013 and to recent developments and then provide an update on our products, followed by a discussion of our financial performance for the year. Finally, we’ll outline our strategy for 2014, before opening the call to any questions. So let’s begin.
If you’ve been following the Company over the past year you’re well aware that 2013 brought new challenges, testing the entire Cumberland organization. I’m pleased to report that our team rose to the occasion and has never been more energized. The Company was faced with the decision you see on whether to change strategy, given the FDA’s approval of a generic competitor to our Acetadote product. Should we preserve our corporate infrastructure or enact significant expense reductions to maintain profitability which could jeopardize our development and commercial capabilities.
Given our ability to respond to the challenges the potential of our marketed and pipeline products as well as our financial strength, we determine that staying the course with the best approach for building the future value of our company. We developed a company wide action plan, with specific objectives that have been successfully executing them. We did not standstill when Acetadote our largest revenue product came under generic competition. We deployed a counter measure strategy in a timely highly fashion.
We quickly launched our authorized generic to Perrigo company in order to also participate in the generic segment of the market. And as a reminder, both Acetadote and our authorized generic contain our new formulation which is free of any preservatives, stabilizing or chelating agents. As a result I am pleased to report that in 2013, we were able to maintain a majority share of the market between the sales of the Acetadote and our authorized generic. Also in 2013, we brought a heightened focus of business development to help reestablish our path to profitability and top line growth that goal also yields positive results as we now have two exciting new products, which are generating considerable enthusiasm within the reins of Cumberland.
Today, we are very pleased to announce the addition of a fifth commercial product to our portfolio, Vaprisol an injectable hospital product used in the critical care setting represents a very complementary addition for our hospital sales force. This patent product was developed and registered by Astellas and launched in 2006.It is one of two branded prescription products indicated for the treatment of hyponatremia and an electrolyte disturbance in which the sodium ion concentration in the plasma is lower than normal.
This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium to appropriate levels and promotes free water secretion. We are pleased to work with Astellas to acquire and transfer this valuable brand.
Our other new product is Omeclamox-Pak, which we added to our portfolio last fall. We launched our efforts to support this brand in January of this year. Our partner for this product Pernix Therapeutics continues to promote Omeclamox to the primary care community. Our field sales force promote to gastroenterologists which are the most productive prescriber – represents the most productive prescriber base for this product. As a result of these two new product additions Cumberland’s revenue stream have never been more diversified and we are very optimistic about our future.
Other highlights in 2013, include Caldolor becoming our fastest growing product with sales nearly doubling over the prior year. During the year we continued developing important new clinical data to support Caldolor for use in both adults and in children. On the international front, we added agreements to register and commercialize Caldolor in The Pacific Rim, South America, and The Arabian Peninsula.
Registration activities for Caldolor progress through our existing partnerships in China, India and Indonesia, and we are also supporting the products commercialization in Canada, Australia and South Korea. Furthermore, we believe we can deliver important new products to our internal development team, which is responsible for taking two of our products to the FDA approval process. Our lead development candidate is Hepatoren, which we continue to progress in 2013 through a Phase II study in patient suffering from life threatening liver and kidney failure.
Well, as you just heard our management team has been working diligently to return Cumberland to profitability and to renew our growth trajectory. Our goal is to continue to build a diversified portfolio of specialty Pharmaceutical products. We are continuing our business development efforts and delighted with the recent agreements for both Omeclamox-Pak and Vaprisol. We feel that both these brands are excellent strategic fits for our company as a complement to our core focus.
I’d now like to ask Marty Cearnal to provide an update on our marketed products. Marty?
Martin E. Cearnal
Thank you, A.J. Let’s begin with our newest products; Vaprisol and Omeclamox-Pak. We are excited about the addition of Vaprisol, our newest injectable hospital product. As A.J. mentioned, that’s used in hyponatremia in the hospital critical care setting. Vaprisol has been commercially available since 2006, but it’s not been actively promoted since 2012. Our first order of business will be to seamlessly transfer the commercial supply, distribution and medical support of the product to ensure no disruption in the marketplace.
Meanwhile, we are beginning preparations to relaunch active promotion by our hospital sales force during the first half of the year. Then we will build upon this initial experience and fine-tune our sales and marketing activities to highlight those product attributes that resonate with prescribers and support our efforts to grow this new brand. These products overlays well with our existing calling efforts with the hospital sales force, which will feature Vaprisol along side our Caldolor and Acetadote brands.
Our second new products is Omeclamox-Pak. We launched our commercial efforts to promote this brand in January. Cumberland promotes the product to gastroenterologists across the United States through our field sales force, which also promotes our Kristalose brand.
As you may know, many stomach ulcers are caused by an infection from the bacteria Helicobacter pylori or H. pylori, which colonize in the stomach and duodenum. When present, this bacterial infection has been proven to be the cause of over 90% of duodenal ulcers. These ulcers commonly cause abdominal pain and may lead to serious bleeding. In the United States the prevalence of H. pylori is approximately 30% to 40% in adults and its eradication has been shown to reduce the risk of duodenal ulcer reoccurrence.
Omeclamox-Pak is a branded prescription product that combines three key ingredients; omeprazole, amoxicillin and clarithromycin for the treatment of H. pylori infection and related ulcer disease. Omeclamox is prescribed over a shortened treatment period of 10 days and has the lowest fee burden of available combination products to treat H. pylori. Together, these attributes causes the opportunity for higher compliance, which is so important in antibiotic therapy. With over half of these prescriptions written by gastroenterologists we believe that Omeclamox is an excellent fit for our field sales organization.
As we move into 2014, we can see result we’ll continue to see treating EDTA-free message at all levels, distribution and promotion. We continue to maintain sales promotion coverage at key medical facilities and at all points and control centers combined with Cumberland taking lead promotional strategies that will initially focused on selected accounts before expanding to broader coverage of additional medical facilities.
Caldolor is now available over 1,000 medical facilities across the United States. Our hospital course is expanding the products use and helping many more patients with these key accounts that have already start to brand. We will continue with that pull through strategy in 2014 to build volumes and increase the number of patients treated in already stocked accounts. We will also be launching new promotional and medical initiatives to support the Caldolor brand.
We’ve launched a new marketing strategy to Kristalose positioning the product at higher price, more in line with the other branded products in this category. This new strategy will allow us to better support the product for patients and offer new opportunities to partner with managed care providers.
We will continue to feature Kristalose with promotional campaigns covering all high potential uses of the product. We are also utilizing a new couponing program with an e-prescribing feature to enhance patient access to Kristalose.
That completes the update on our marketed brands, and I’ll turn it over to Rick Greene for a financial review.
Rick S. Greene
Thank you, Marty. For the full year ended December 31, 2013, Cumberland’s net revenues were $32 million compared to $48.9 million in the prior year. Net revenue for Acetadote in 2013 was $80.8 million compared to $37.5 million in 2012. Acetadote revenue included $9.2 million from our authorized generic in 2013 compared to $0.3 million in 2012.
Net revenue for Kristalose in 2013 was $9.1 million, similar to the prior year. Net revenue for Caldolor in 2013 was $2.1 million, more than doubling the prior year sales. Our newest product, Omeclamox-Pak, contributed $1 million of revenue in 2013.
During the fourth quarter of 2013, net revenues were $8.1 million, down from $13.7 million during the corresponding period in 2012. For the three months ended December 31, 2013, net revenues were $3.7 million for Acetadote, including $2.2 million from our authorized generic, $2.8 million for Kristalose, $1 million for Omeclamox-Pak and $600,000 for Caldolor.
For the year ended December 31, 2013, our total operating expenses were $35.8 million compared to $40 million for 2012. Total operating expenses for the three months ended December 31, 2013 were $10.6 million compared to $10.4 million for the prior year period.
We ended 2013 with a net loss of $2.2 million, compared to net income of $5.8 million in 2012. The net loss for the fourth quarter was $1.5 million, compared to net income of $1.8 million for the same period in 2012.
Diluted loss per share for the year ended December 31, 2013, was $0.11, compared to earnings per share of $0.30 for 2012. Diluted loss per share for the fourth quarter was $0.08, compared $0.09 in earnings for the fourth quarter of 2012. At the end of the year we had $54.9 million in cash reserves, which included cash, cash equivalents and marketable securities.
Total assets at December 31, 2013, were $87.6 million, compared to $98.6 million at the end of 2012. We were cash flow positive from operations during 2013. During the year we used cash to pay off our line of credit, invest NOIs for Omeclamox-Pak, fund our Acetadote defense, patent defense and continue our share repurchase program. During 2013, we actively repurchased Cumberland shares and have now bought back a total of 3.5 million shares since we launched the initiative in 2010.
That completes the financial report for both the full year and the fourth quarter of 2013. I’ll turn it back over to you, A. J.
A. J. Kazimi
Thanks, Rick. I’d like to take a brief moment to summarize our strategic focus for 2014 as we managed the company in a way to maximize the next phase of Cumberland’s growth. Our plan for 2014 is to continue to build a diversified specialty product portfolio while deploying our resources to sustain long-term profitability. We’re very optimistic about the opportunities that Vaprisol and Omeclamox-Pak will offer Cumberland. Our sales organization is enthusiastic about promoting both of these products. Our company will continue to monitor market conditions and fully support our Caldolor, Kristalose and Acetadote brands.
We’ll focus our development efforts on accelerating our pipeline candidates while also advancing new clinical programs. We will conclude the analysis, reports and publications for the completed Caldolor study and update the comprehensive safety and efficacy data set for that product. We plan to continue expansion of our international activities through selectively chosen partners and will organize our manufacturing network in order to establish an uninterrupted supply of high quality products.
We want to maintain our new momentum in business development and continue to pursue additional opportunities to acquire new commercial or late-stage development products. Management remains committed to maintaining a strong balance sheet, returning the company to profitability and placing revenues back on the growth trajectory. We do expect to return the company to profitability for the full year 2014. We believe our stock represents an attractive investment opportunity and we’ll continue repurchasing shares with excess cash.
So in closing, while we faced new challenges in 2013, we emerged here in 2014 with a leaner, more diversified company, powered by an outstanding team of individuals throughout this organization and I would like to take this opportunity to thank each of them for their dedicated efforts and many contributions.
The interest of this organization, its management and our shareholders remain closely aligned. We’ll continue to focus on our mission of improving patient care through the delivery of high quality pharmaceutical products.
With that, let’s open the call to any questions. Operator, please proceed.
Thank you, sir. Ladies and gentlemen, that concludes the company’s presentation. We’ll now call for questions. (Operator Instructions) And I see no questions at this time. I would like to turn the call back over to management for any closing remarks.
A. J. Kazimi
Okay. I just want to everyone for joining our call today. We do appreciate your time and interest in Cumberland and we look forward to providing with another update following the close of the first quarter.
Thank you, sir. Ladies and gentlemen, that concludes our conference for today. If you would like to listen to a phone replay of today’s conference, please dial 855-859-2056, using the access code 24879662, through August 2014. Alternatively, a replay of the webcast will be available on the company’s Investor Relations website. I would like to thank you for your participation. You may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.org. Thank you!